Please assess the completion status of the following clinical trial:

Trial Title: Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Solid tumor with brain metastases.~* Patients at the age of 18-65.~* Patients undergo tumor resection or biopsy.~* Patients with Karnofsky scores \> or =70~* Patients with normal range of hematologic and metabolic test results.~* Patients must have no corticosteroids treatment at least one week before vaccination.~* Patients capable of understanding the study and signed informed consent.~Exclusion Criteria:~* Infectious diseases HIV, HBV, HCV.~* Documented immunodeficiency.~* Documented autoimmune disease.~* Breast feeding females.~* Pregnant women.~* Any serious or uncontrolled medical or psychiatric conditions, for example, severe pulmonary, cardiac or other systemic disease.~* Patient inability to participate as determined by PI discretion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Personalized cellular vaccine (Type: EXPERIMENTAL): Patients will undergo tumor resection or biopsy, and receive biweekly cellular vaccines consisting of mRNA-pulsed autologous DCs.

Based on this trial design, predict the completion outcome and termination type (if applicable).